Sigma Planning Corp’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.66M | Buy |
8,434
+3,174
| +60% | +$612K | 0.05% | 389 |
|
|
2025
Q4 | $967K | Buy |
5,260
+2,958
| +128% | +$519K | 0.03% | 547 |
|
|
2025
Q3 | $353K | Buy |
2,302
+2
| +0.1% | +$303 | 0.01% | 965 |
|
|
2025
Q2 | $321K | Buy |
2,300
+35
| +2% | +$4.91K | 0.01% | 965 |
|
|
2025
Q1 | $333K | Buy |
2,265
+209
| +10% | +$30.2K | 0.01% | 908 |
|
|
2024
Q4 | $269K | Sell |
2,056
-255
| -11% | -$35.7K | 0.01% | 974 |
|
|
2024
Q3 | $360K | Sell |
2,311
-413
| -15% | -$66.7K | 0.01% | 881 |
|
|
2024
Q2 | $425K | Sell |
2,724
-1,045
| -28% | -$157K | 0.01% | 797 |
|
|
2024
Q1 | $511K | Buy |
3,769
+1,169
| +45% | +$155K | 0.02% | 751 |
|
|
2023
Q4 | $350K | Sell |
2,600
-7,221
| -74% | -$939K | 0.03% | 580 |
|
|
2023
Q3 | $1.33M | Sell |
9,821
-357
| -4% | -$48.8K | 0.05% | 372 |
|
|
2023
Q2 | $1.46M | Sell |
10,178
-661
| -6% | -$97.3K | 0.05% | 354 |
|
|
2023
Q1 | $1.5M | Buy |
10,839
+4,171
| +63% | +$561K | 0.05% | 372 |
|
|
2022
Q4 | $904K | Sell |
6,668
-17
| -0.3% | -$2.13K | 0.03% | 525 |
|
|
2022
Q3 | $733K | Sell |
6,685
-374
| -5% | -$47.4K | 0.03% | 577 |
|
|
2022
Q2 | $933K | Buy |
7,059
+387
| +6% | +$50.8K | 0.03% | 490 |
|
|
2022
Q1 | $885K | Sell |
6,672
-14
| -0.2% | -$1.68K | 0.03% | 591 |
|
|
2021
Q4 | $779K | Sell |
6,686
-2,117
| -24% | -$249K | 0.02% | 647 |
|
|
2021
Q3 | $1.06M | Sell |
8,803
-150
| -2% | -$17.5K | 0.03% | 517 |
|
|
2021
Q2 | $1.07M | Sell |
8,953
-493
| -5% | -$54.1K | 0.03% | 530 |
|
|
2021
Q1 | $939K | Buy |
9,446
+1,638
| +21% | +$165K | 0.03% | 524 |
|
|
2020
Q4 | $781K | Sell |
7,808
-2,952
| -27% | -$313K | 0.03% | 519 |
|
|
2020
Q3 | $1.18M | Buy |
10,760
+5,616
| +109% | +$625K | 0.05% | 362 |
|
|
2020
Q2 | $544K | Buy |
5,144
+2,269
| +79% | +$234K | 0.02% | 562 |
|
|
2020
Q1 | $257K | Sell |
2,875
-4,402
| -60% | -$414K | 0.02% | 701 |
|
|
2019
Q4 | $726K | Buy |
7,277
+47
| +0.7% | +$4.42K | 0.03% | 486 |
|
|
2019
Q3 | $645K | Sell |
7,230
-336
| -4% | -$29.1K | 0.03% | 488 |
|
|
2019
Q2 | $625K | Sell |
7,566
-108
| -1% | -$8.47K | 0.03% | 479 |
|
|
2019
Q1 | $621K | Sell |
7,674
-183
| -2% | -$14.4K | 0.04% | 452 |
|
|
2018
Q4 | $597K | Buy |
7,857
+3,647
| +87% | +$285K | 0.04% | 387 |
|
|
2018
Q3 | $333K | Buy |
4,210
+68
| +2% | +$5.14K | 0.02% | 645 |
|
|
2018
Q2 | $291K | Sell |
4,142
-338
| -8% | -$24.3K | 0.02% | 656 |
|
|
2018
Q1 | $313K | Buy |
4,480
+327
| +8% | +$22.7K | 0.02% | 597 |
|
|
2017
Q4 | $288K | Sell |
4,153
-269
| -6% | -$18.1K | 0.02% | 622 |
|
|
2017
Q3 | $300K | Sell |
4,422
-4,678
| -51% | -$296K | 0.02% | 606 |
|
|
2017
Q2 | $620K | Sell |
9,100
-138
| -1% | -$9.01K | 0.06% | 349 |
|
|
2017
Q1 | $575K | Buy |
+9,238
| New | +$538K | 0.06% | 355 |
|
|
2016
Q4 | – | Sell |
-8,453
| Closed | -$556K | – | 739 |
|
|
2016
Q3 | $556K | Sell |
8,453
-201
| -2% | -$13.1K | 0.07% | 312 |
|
|
2016
Q2 | $523K | Buy |
+8,654
| New | +$503K | 0.07% | 312 |
|
|
2015
Q1 | – | Sell |
-3,202
| Closed | -$225K | – | 755 |
|
|
2014
Q4 | $225K | Buy |
+3,202
| New | +$229K | 0.03% | 600 |
|
Other funds holding AZN
IA
VCM
VAM
Sigma Planning Corp's AZN Position: Q1 2026 in Review
Sigma Planning Corp increased its AstraZeneca (AZN) stake by 60% in Q1 2026, buying an estimated $612K and bringing the position to 8,434 shares worth $1.66M. The position accounts for 0.05% of the portfolio, ranked #389.
Sigma Planning Corp first reported a position in AZN in Q4 2014 and has held it in 40 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.
- Sigma Planning Corp held 8,434 shares of AstraZeneca worth $1.66M as of Q1 2026.
- Sigma Planning Corp bought 3,174 AstraZeneca shares in Q1 2026, an estimated $612K.
- AstraZeneca made up 0.05% of Sigma Planning Corp's portfolio in Q1 2026, its #389 holding.
- Sigma Planning Corp first reported a position in AstraZeneca in Q4 2014 and has held it in 40 quarters since.
- 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.
Based on Sigma Planning Corp's 13F filing for Q1 2026, filed 4 May 2026.